Comparison of the Effect of Azithromycin Versus Erythromycin on Antroduodenal Pressure Profiles of Patients with Chronic Functional Gastrointestinal Pain and Gastroparesis
- 1.3k Downloads
Current pharmacologic treatments for gastroparesis have been disappointing due to the limited options available. Erythromycin ethylsuccinate is a potent prokinetic agent that stimulates gastric emptying. Recently, erythromycin has been linked to the occurrences of sudden cardiac death due to QT prolongation. Azithromycin is similar to erythromycin in structure but does not have significant drug–drug interactions as seen with erythromycin.
This study aims to determine whether azithromycin stimulates antral activity in patients with chronic gastrointestinal pain and refractory gastroparesis.
Small bowel manometric data on 30 patients undergoing clinical evaluation for chronic digestive problems or documented refractory gastroparesis were reviewed. Antral activity was measured after infusion of erythromycin 250 mg intravenous and azithromycin (500 or 250 mg intravenous) given at different intervals during the small bowel manometry. The parameters measured included the total duration of effect, mean amplitude of antral contractions, duration of the highest antral contraction phase, number of cycles per minute, and the motility index.
Comparison of erythromycin and azithromycin at similar doses showed a similar positive effect on antral activity. However, comparison of erythromycin and azithromycin at the higher dose of 500 mg showed that the mean amplitude, duration of antral activity, and motility index were significantly increased with azithromycin (P < 0.05).
Azithromycin stimulates antral activity similar to erythromycin and moreover has a longer duration of effect. However, unlike erythromycin, azithromycin does not have significant drug–drug interactions and may be a potential new medication for the treatment of gastroparesis and gastrointestinal dysmotility.
KeywordsGastroparesis Gastrointestinal dysmotility Functional gastrointestinal pain Antroduodenal manometry Erythromycin Azithromycin
- 4.Joshi P, Toskes PP. Clinical approach to chronic pancreatitis. J Clin Outcomes Manage. 2005;12(8):419–428.Google Scholar
- 5.Malagelada Jr, Stanghellini V. Manometric evaluation of functional upper gut symptoms. Gastroentererology. 1985;88(5 Pt 1):1223–1231.Google Scholar
- 18.Wisialowski T, Crimin K, Engtrakul J, O’Donnell J, Fermini B, Fossa AA. Differentiation of the antibacterials moxifloxacin, erythromycin and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther. 2006;318(1):352–359.CrossRefPubMedGoogle Scholar
- 19.Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof, Fabritz L, Breithardt G, Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002; 303(1): 218–225.Google Scholar
- 22.Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther. 2009 Mar 27 [Epub ahead of print].Google Scholar
- 37.Bologna SD, Hasler WL, Owyang C. Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther. 1993;226(2):852–856.Google Scholar
- 39.Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with, without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14(12):1653–1661.CrossRefPubMedGoogle Scholar
- 40.Depoortere I, Peeters TL, Matthijs G, Cachet T, Hoogmartens J, Vantrappen G. Structure-activity relation of erythromycin related macrolides in inducing contractions and displacing bound motilin in rabbit duodenum. J Gastrointest Motil. 1989;1:150–159.Google Scholar